Mounting evidence suggests that SGLT2 inhibition may inhibit the growth of SGLT2-expressing carcinomas, including breast cancer [12], cervical cancer [13], hepatocellular cancer [14], prostate cancer, and lung cancer [15]. This evidence concerns the gene SLC5A2 and cervical cancer.